A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Latest Information Update: 04 Aug 2023
At a glance
- Drugs Dupilumab (Primary) ; Fluticasone furoate; Levosalbutamol; Mometasone/formoterol; Salbutamol; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 03 Aug 2023 Results of post-hoc analysis assessing long-term efficacy in type 2 patients with and without evidence of allergic asthma who enrolled in TRAVERSE from Phase 3 QUEST (NCT02414854) and Phase 2b (NCT01854047) studies, published in the Journal of Asthma.
- 03 Oct 2020 Results assessing whether Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids published in the Allergy
- 20 May 2020 Results of meta-analyses of phase 3 QUEST (NCT02414854; N = 1,902) and phase 2b (NCT01854047; N = 465) studies has been presented at the 116th International Conference of the American Thoracic Society.